GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Roivant Sciences
Who Owns Roivant Sciences?
Understanding Roivant Sciences' ownership is key to its strategy and accountability. A major step was its Nasdaq listing in October 2021 via a SPAC merger. Founded in 2014 by Vivek Ramaswamy, the company aims to transform drug development.
Roivant's 'Vant' model aims to speed up drug development and commercialization, bringing new treatments to patients faster. This approach has positioned it as a significant player in the healthcare sector, with its Roivant Sciences BCG Matrix analysis showing its diverse portfolio.
As of March 31, 2024, Roivant reported revenues of US$125 million and total assets of US$7.22 billion. The company's equity stood at US$6.45 billion. By early 2024, its market capitalization was around $9 billion, a significant increase from over $6 billion in February 2023. Roivant Sciences employed 908 people in 2024.
Who Founded Roivant Sciences?
Roivant Sciences was established in 2014 by Vivek Ramaswamy, who envisioned a novel approach to drug development. His strategy centered on in-licensing promising drug candidates and creating specialized subsidiary companies, each focused on a particular therapeutic area. This model aimed to streamline and accelerate the journey of new medicines from the lab to patients.
Founding Vision
Vivek Ramaswamy founded Roivant Sciences in 2014 with a unique strategy. The company focuses on in-licensing drug candidates and establishing dedicated subsidiaries for specific therapeutic areas.
Early Funding
Roivant Sciences secured substantial early financial backing. In 2015, the company raised approximately $100 million in its initial major financing round.
Initial Investors
Key early investors included the Dexxon investor group, with Dexcel Pharma as a participant. Viking Global Investors also made its first investment in December 2015.
The 'Vant' Model
The early capital infusion was crucial for launching Roivant's distinctive 'Vant' model. This structure allows for focused development within specialized subsidiary companies.
Strategic Focus
The founding team's vision was to accelerate drug development through these focused subsidiary companies. This approach was enabled by the initial funding secured by Roivant Sciences.
Ownership Details
Specific equity splits or shareholdings at the company's inception are not publicly detailed. However, the early backing laid the groundwork for its corporate structure.
Early Ownership Landscape
The initial ownership of Roivant Sciences was shaped by its founder, Vivek Ramaswamy, and its early investors who provided critical capital. This foundational period established the company's unique operational model and its trajectory in the biopharmaceutical industry. Understanding these early stakeholders is key to grasping the company's evolution and its current Mission, Vision & Core Values of Roivant Sciences.
- Founder: Vivek Ramaswamy
- Initial Financing: Approximately $100 million in 2015
- Key Early Investors: Dexxon investor group (including Dexcel Pharma), Viking Global Investors
- Strategic Model: In-licensing drug candidates and creating specialized subsidiaries
Complete Roivant Sciences Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
How Has Roivant Sciences’s Ownership Changed Over Time?
Roivant Sciences' ownership journey has seen significant transformations, notably marked by a substantial equity investment in August 2017 and its public debut in October 2021. These events reshaped its stakeholder landscape and financial foundation.
| Event | Date | Impact |
|---|---|---|
| Equity Investment | August 2017 | $1.1 billion infusion led by SoftBank Vision Fund to accelerate subsidiary launches. |
| Public Merger | October 1, 2021 | Merger with Montes Archimedes Acquisition Corp., listing on Nasdaq (ROIV). |
| Partnership with Sumitomo Dainippon Pharma | 2019 | $3 billion deal transferring ownership of five subsidiaries to Sumitovant Biopharma. |
| Acquisition by Roche | December 2023 | Sale of Telavant for $7.1 billion upfront and $150 million milestone payment. |
As a publicly traded entity on Nasdaq under the ticker ROIV, Roivant Sciences' ownership is now distributed among various investor types. As of July 28, 2025, the company's share price stood at $11.35. Institutional investors are major stakeholders, with 597 entities holding a combined 613,792,467 shares as of March 31, 2025, representing approximately 89.83% of their total positions. Key institutional shareholders include QVT Financial LP, SB Investment Advisers (UK) Ltd, Fmr Llc, Viking Global Investors Lp, BlackRock, Inc., and Vanguard Group Inc. Insiders collectively own about 27.97% of the company's stock, while public companies and individual investors hold approximately 45.03%. The founder, Vivek Ramaswamy, held a 10.5% stake as of March 31, 2024. Strategic transactions, such as the 2019 partnership with Sumitomo Dainippon Pharma and the December 2023 sale of Telavant to Roche, have significantly influenced Roivant's financial standing, contributing to its cash and equivalents reaching $5.7 billion in Q1 2025.
Key Stakeholders in Roivant Sciences
Understanding Roivant Sciences' ownership structure reveals a diverse group of investors and strategic partners.
- Institutional investors hold the largest percentage of shares.
- The company's founder, Vivek Ramaswamy, remains a significant stakeholder.
- Strategic partnerships and acquisitions have shaped its ownership evolution.
- Public companies and individual investors also contribute to the ownership base.
- The company's public listing on Nasdaq provides broad accessibility for investors.
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
Who Sits on Roivant Sciences’s Board?
Roivant Sciences' Board of Directors is tasked with upholding the company's corporate governance standards and ensuring compliance. While specific affiliations of board members to major shareholders are not always detailed in public summaries, the company's investor relations website provides access to its corporate governance guidelines and board composition.
| Board Responsibility | Key Function | Governance Aspect |
|---|---|---|
| Setting Corporate Governance Standards | Establishing company-wide policies | Compliance and ethical conduct |
| Oversight of Compliance | Ensuring adherence to regulations | Legal and regulatory framework |
| Director Election | Approving board appointments | Shareholder voting power |
Roivant Sciences operates under a one-share-one-vote system for its common shares. As of July 17, 2024, the company had 739,183,842 common shares outstanding and eligible to vote. This structure allows Roivant, as the majority stockholder in its publicly traded subsidiaries like Immunovant, to exert significant control over matters requiring shareholder approval, including director elections. For instance, Immunovant is considered a 'controlled company' by Nasdaq as long as Roivant maintains at least 50% of the voting power for director elections, which provides exemptions from certain Nasdaq listing rules concerning independent directors and committees. Notably, Vivek Ramaswamy stepped down from Roivant's board on February 21, 2023, to pursue his presidential campaign, having previously transitioned from his CEO role in January 2021. Matt Gline currently serves as the CEO of Roivant Sciences.
Understanding Roivant Sciences' Ownership and Governance
Roivant Sciences employs a straightforward voting structure for its common shares. The company's majority ownership in subsidiaries like Immunovant grants it considerable influence.
- One-share-one-vote structure for common shares.
- Roivant is the majority stockholder in subsidiaries like Immunovant.
- Majority ownership allows control over director elections.
- Vivek Ramaswamy is no longer on the board; Matt Gline is the current CEO.
- Understanding Revenue Streams & Business Model of Roivant Sciences is key to grasping its overall structure.
Roivant Sciences Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What Recent Changes Have Shaped Roivant Sciences’s Ownership Landscape?
Roivant Sciences has experienced significant shifts in its ownership landscape over the past few years, marked by strategic acquisitions and public market activities. These developments reflect the company's evolving business model and its success in monetizing its portfolio companies.
| Event | Date | Details |
|---|---|---|
| Acquisition of Silicon Therapeutics | February 2021 | $450 million in Roivant equity |
| Upsized Public Offering | February 2023 | 26,666,666 common shares at $7.50 per share, raising $200 million |
| Primary and Secondary Public Offering | November 2022 | 30,000,000 common shares at $5.00 per share, raising $100 million for Roivant and $50 million for selling shareholders |
| Acquisition of Telavant by Roche | December 2023 | $7.1 billion upfront plus milestone payments |
The acquisition of Telavant by Roche for up to $7.1 billion in December 2023 highlights the substantial value Roivant Sciences can unlock through its Vant model. This transaction underscores the company's ability to foster innovation and generate significant returns for its stakeholders. Roivant Sciences is publicly traded, and its ownership structure includes a substantial presence of institutional investors, indicating broad market confidence. The company's financial performance, as seen in its Q1 2025 results (ended June 30, 2024), shows a net income of $57 million and net revenues of $55 million, with product revenues of $18 million, primarily from VTAMA. This financial strength is supported by a robust cash position of $5.7 billion.
Institutional Investor Activity
Roivant Sciences benefits from significant backing by institutional investors. Currently, 597 institutional owners hold a considerable stake in the company, reflecting widespread investment interest.
Insider Transactions
Insider trading activity remains a point of interest, with notable transactions by key figures. For instance, Vivek Ramaswamy engaged in transactions in June 2025.
Financial Performance and Outlook
The company reported a net income of $57 million for Q1 2025. Roivant Sciences is poised to provide further business updates and financial results for the quarter ending June 30, 2025, on August 11, 2025.
Strategic Monetization
The successful sale of Telavant to Roche for $7.1 billion exemplifies Roivant's capability to monetize its portfolio companies. This demonstrates the effectiveness of its business model in generating substantial returns.
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Brief History of Roivant Sciences Company?
- What is Competitive Landscape of Roivant Sciences Company?
- What is Growth Strategy and Future Prospects of Roivant Sciences Company?
- How Does Roivant Sciences Company Work?
- What is Sales and Marketing Strategy of Roivant Sciences Company?
- What are Mission Vision & Core Values of Roivant Sciences Company?
- What is Customer Demographics and Target Market of Roivant Sciences Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.